Analyst Price Target is $20.00
▲ +46.31% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Astria Therapeutics in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 46.31% upside from the last price of $13.67.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Astria Therapeutics. This Buy consensus rating has held steady for over two years.
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.